Halozyme Therapeutics reported $2.05M in Interest Expense on Debt for its fourth fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Interest Expense On Debt Change
Alnylam Pharmaceuticals ALNY:US $ 42.36M 5.55M
Amgen AMGN:US $ 295M 40M
Cytokinetics CYTK:US $ 2.75M 1.47M
Esperion Therapeutics ESPR:US $ 14.06M 632K
Immunogen IMGN:US $ 1.25M 0.9M
Intrexon XON:US $ 4.8M 0.13M
Nektar Therapeutics NKTR:US $ 8.13M 4.67M
Peregrine Pharmaceuticals PPHM:US 704K 1000